Opsy Holding AB, formerly WntResearch AB, is a Sweden-based company engaged in the translational cancer research. Its aim is to develop anti-metastatic therapies based on an increased understanding of the mechanisms underlying the metastatic process and the evaluation of specific small molecules that can specifically interact with this process. The Companyâ€™s programs focus on the role of the Wnt-5a protein in the metastatic process.

Employees

Sector

Biotechnology & Medical Research

Calendar

08-26 Earnings release - Q2 2026

More about the company

Quotes

Date	Price	Change	Volume
26-08-20	SEK 9.300	-6.53%	27,619
26-08-19	SEK 9.950	-1.49%	4,160
26-08-18	SEK 10.10	+1.00%	3,825
26-08-17	SEK 10.00	-3.85%	2,303
26-08-14	SEK 10.40	+5.05%	10,886

End-of-day quote NORDIC GROWTH MARKET

More quotes

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

End-of-day quote NORDIC GROWTH MARKET 2026-08-19			5-day change	1st Jan Change
9.950 ^SEK	-1.49%		+0.51%	+53.08%

07-28	Opsy decides on directed share issues totaling more than €1.5m	FW
07-08	Opsy increased case volume by 17 percent	FW

Market Cap	138M 14.53M 12.44M 11.61M 10.65M 20.01M 1.39B 20.41M 53.68M 697M 54.56M 53.37M 2.31B	P/E 2024 *	-	P/E 2025	-4.79x
Enterprise Value	138M 14.55M 12.46M 11.62M 10.67M 20.04M 1.39B 20.43M 53.75M 698M 54.63M 53.44M 2.31B	EV / Sales 2024 *	-	EV / Sales 2025	8,542,354x
Free-Float	1.03%	Yield 2024 *	-	Yield 2025	-

07-28	Opsy decides on directed share issues totaling more than €1.5m	FW
07-08	Opsy increased case volume by 17 percent	FW
07-01	Opsy Launches AI Support for Insurance Cases	FW
06-12	Opsy Reaches Milestone of 100 Medical Advisors in Its Network	FW
05-13	CEO and major shareholder Arne Thor increases stake in Opsy	FW
05-11	Opsy signs agreement with Kommunassurans	FW
05-04	Opsys platform surpasses 6,000 completed cases	FW
04-29	Opsys CEO and major shareholder Arne Thor increases stake	FW
04-27	Opsy appoints new CFO	FW
04-26	Opsy Holding AB Announces CFO Changes	CI
04-24	Opsy narrows operating loss	FW
04-24	Opsy Holding AB Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-21	Court refuses to stay intervention against Verisk – clauses terminated with immediate effect	FW

1 day	-1.49%
1 week	+0.51%
Current month	+2.58%
1 month	-0.50%
3 months	-3.40%
6 months	+64.46%
Current year	+53.08%

Opsy Holding AB Stock

Stocks

OPSYH

SE0025399199

Biotechnology & Medical Research

Valuation: Opsy Holding AB

Chart: Opsy Holding AB

Latest news : Opsy Holding AB

Quotes and Performance

Course Extremes

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

1 week	9.8	10.4
1 month	9.25	10.7
Current year	5.05	17.4
1 year	5.05	17.4
3 years	3.6	17.4
5 years	3.6	17.4
10 years	3.6	17.4

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
OPSY HOLDING AB	-1.49%	+0.51%	+50.76%	-	14.57M
WUXI APPTEC CO., LTD.	+2.38%	+5.57%	+86.02%	+115.89%	72.21B
ARGENX SE	+0.87%	+16.32%	+58.35%	+97.28%	63.98B
INSMED INCORPORATED	-4.27%	-0.99%	-3.38%	+468.55%	28.53B
WUXI BIOLOGICS (CAYMAN) INC.	+3.63%	+8.62%	+66.69%	+23.95%	25.07B
BIONTECH SE	-1.97%	+20.38%	-0.37%	-5.65%	28.42B
GENMAB A/S	-0.51%	+5.11%	+41.27%	-12.79%	20.04B
PHARMAESSENTIA CORPORATION	-1.79%	-4.51%	+241.26%	+414.48%	18.19B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+1.81%	+0.85%	+16.89%	+546.06%	15.96B
EXELIXIS, INC.	-1.29%	+6.09%	+41.81%	+151.24%	13.48B
Average	-0.26%	+5.12%	+59.93%	+199.89%	28.59B
Weighted average by Cap.	+0.38%	+7.48%	+61.42%	+162.44%

	2024	2025
Net sales	-	9.68 1.02 0.87 0.82 0.75 1.41 97.77 1.44 3.77 49 3.84 3.75 162.21
Net income	-46.5M -4.91M -4.2M -3.92M -3.6M -6.76M -470M -6.89M -18.13M -235M -18.42M -18.02M -779M	-17.23M -1.82M -1.56M -1.45M -1.33M -2.5M -174M -2.55M -6.72M -87.19M -6.83M -6.68M -289M
Net Debt	-5.26M -555K -475K -443K -407K -764K -53.09M -779K -2.05M -26.61M -2.08M -2.04M -88.08M	185K 19.52K 16.71K 15.59K 14.31K 26.89K 1.87M 27.42K 72.12K 936K 73.3K 71.7K 3.1M